Endoglin: Structure, biological functions, and role in fibrogenesis;Endoglina: Estructura, funciones biológicas y papel en la fibrogénesis

Revista Espanola de Enfermedades Digestivas

Volumn 100, Issue 6, 2008, Pages 355-360

  Garcia Pozo L ^a   Miquilena Colina, M E ^a   Lozano Rodriguez T ^a   García Monzón, Carmelo ^a  

^a HOSPITAL UNIVERSITARIO SANTA CRISTINA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ENDOGLIN; TRANSFORMING GROWTH FACTOR BETA;

FIBROGENESIS; HUMAN; PROTEIN FUNCTION; PROTEIN STRUCTURE; REVIEW;

ANIMALS; ANTIGENS, CD; FIBROBLASTS; FIBROSIS; HUMANS; LIVER CIRRHOSIS; RECEPTORS, CELL SURFACE; TRANSFORMING GROWTH FACTOR BETA;

EID: 49749149514     PISSN: 11300108     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (65)

1. Gougos A, Letarte M. Identification of a human endothelial cell antigen with monoclonal antibody 44G4 produced against a pre-B leukemic cell line. J Immunol 1988; 141: 1925-33.
2. Lastres P, Bellón T, Cabañas C, Sánchez-Madrid F, Acevedo A, Gougos A, et al. Regulated expression on human macrophages of endoglin, an Arg-Gly-Asp-containing surface antigen. Eur J Immunol 1992; 22: 393-7.
3. Bürhing HJ, Müller CA, Letarte M, Gougos A, Saalmüller A, von Agthoven AJ, Busch FW. Endoglin is expressed on a subpopulation of inmature erythroid cells of normal human bone marrow. Leukemia 1991; 5: 841-7.
4. Gougos A, St Jacques S, Greaves A, O'Connell PJ, d'Apice AJF, Bürhing HJ, et al. Identification of distinct epitopes of endoglin, an RGD-containing glycoprotein of endothelial cells, leukemic cells, and syncytiotrophoblasts. Intern Immunol 1992; 4: 83-92.
5. St Jacques S, Cymerman U, Pece N, Letarte M. Molecular characterization and in situ localization of murine endoglin reveal that it is a transforming growth factor-β binding protein of endothelial and stromal cells. Endocrinology 1994; 134: 2645-57.
6. Fernández-Ruiz E, St Jacques S, Bellón T, Letarte M, Bernabéu C. Assignment of the human endoglin gene (END) to chromosome 9q34-qter. Cytogenet Cell Genet 1993; 64: 204-7.
7. McAllister KA, Grogg KM, Johnson DW, Gallione CJ, Baldwin MA, Jackson CE, et al. Endoglin, a TGF-β binding protein of endothelial cells, is the gene for hereditary haemorrhagic telangiectasia type 1. Nature Genet 1994; 8: 345-51.
8. Cheifetz S, Bellón T, Calés C, Vera S, Bernabéu C, Massagué J, et al. Endoglin is a component of the transforming growth factor-β receptor system in human endothelial cells. J Biol Chem 1992; 267: 19027-30.
9. Duff SE, Li C, Garland JM, Kumar S. CD105 is important for angiogenesis: Evidence and potential applications. FASEB J 2003; 17: 984-92.
10. Bourdeau A, Dumont DJ, Letarte M. A murine model of hereditary hemorrhagic telangiectasia. J Clin Invest 1999; 104: 1343-51.
11. Li C, Hampson IN, Hampson L, Kumar P, Bernabeu C, Kumar S. CD105 antagonizes the inhibitory signaling of transforming growth factor β1 on human endothelial vascular cells. FASEB J 2000; 14: 55-64.
12. Sorensen LK, Brooks BS, Li DY, Umess LD. Loss of distinct arterial and venous boundaries in mice lacking endoglin, a vascular-specific TGFbeta coreceptor. Dev Biol 2003; 261: 235-50.
13. Fonsatti E, Altomonte M, Nicostra MR, Natali PG, Maio M. Endoglin (CD105): A powerful therapeutic target on tumor-associated angiogenic blood vessels. Oncogene 2003; 22: 6557-63.
14. Maio M, Altomonte M, Fonsatti E. It is the prime time for endoglin (CD105) in the clinical setting? Cardiovasc Res 2006; 69: 781-3.
15. Roy-Chaudhury P, Simpson JG, Power DA. Endoglin, a transforming growth factor-beta-binding protein, is upregulated in chronic progressive renal disease. Exp Nephrol 1997; 5: 55-60.
16. García-Monzón C, Sánchez-Madrid F, García-Buey L, García-Arroyo A, García-Sánchez-A, Moreno-Otero R. Vascular adhesion molecule expression in viral chronic hepatitis: Evidence of neoangiogenesis in portal tracts. Gastroenterology 1995; 108: 231-41.
17. Gougos A, Letarte M. Primary structure of endoglin, an RGD-containing glycoprotein of human endothelial cells. J Biol Chem 1990; 265: 8361-4.
18. Bellón T, Corbi A, Lastres P, Cales C, Cebrian M, Vera S, et al. Identification and expression of two forms of the transforming growth factor-beta-binding protein endoglin with distinct cytoplasmic regions. Eur J Immunol 1993; 23: 2340-5.
19. Bork P, Sander C. A large domain common to sperm receptors (ZP2 and ZP3) and TGF-beta type III receptor. FEBS letters 1992; 300: 237-40.
20. Jovine L, Darie CC, Litscher ES, Wassarman PM. Zona pellucida domain proteins. Annu Rev Biochem 2005; 74: 83-114.
21. Guerrero-Esteo M, Lastres P, Letamendia A, Pérez-Álvarez MJ, Langa C, López IA, et al. Endoglin overexpression modulates cellular morphology, migration, and adhesion of mouse fibroblasts. Eur J Cell Biol 1999; 78: 614-23.
22. Guo B, Rooney P, Slevin M, Li C, Parameshwar S, Liu D, et al. Overexpression of CD105 in rat myoblasts: Role of CD105 in cell attachment, spreading and survival. Int J Oncol 2004; 25: 285-91.
23. Llorca O, Trujillo A, Blanco FJ, Bernabéu C. Structural model of human endoglin, a transmembrane receptor responsible for hereditary hemorrhagic telangiectasia. J Mol Biol 2007; 365 (3): 694-705.
24. Jovine L, Qi H, Williams Z, Litscher ES, Wassarman PM. The ZP domain is conserved module for polymerization of extracellular proteins. Nature Cell Biol 2002; 4: 457-61.
25. Abdalla SA, Letarte M. Hereditary haemorrhagic telangiectasia: Current views on genetics and mechanisms of disease. J Med Genet 2006; 43: 97-110.
26. Lastres P, Letamendía A, Zhang H, Rius C, Almendro N, Raab U, et al. Endoglin modulates cellular responses to TGF-β1. J Cell Biol 1996; 131: 1109-21.
27. Fernández-L A, Sanz-Rodríguez F, Blanco FJ, Bernabéu C, Botella LM. Hereditary hemorrhagic telangiectasia, a vascular dysplasia affecting the TGF-β signaling pathway. Clin Med Res 2006; 4: 66-78.
28. Jerkic M, Rodríguez-Barbero A, Prieto M, Toporsian M, Pericacho M, Rivas-Elena JV, et al. Reduced angiogenic responses in adult Endoglin heterozygous mice. Cardiovascular Res 2006; 69: 845-54.
29. McDonald MT, Papenberg KA, Ghosh S, Glatfelter AA, Biesecker BB, Helmbold EA, et al. A disease locus for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat Genet 1994; 6: 197-204.
30. Shovlin CL, Hughes JM, Tuddenham EG, Temperley I, Perembelon YF, Scott J, et al. A gene for hereditary haemorrhagic telangiectasia maps to chromosome 9q33-34. Nat Genet 2004; 6: 205-9.
31. Johnson DW, Berg JN, Baldwin MA, Gallione CJ, Marondel I, Yoon SJ, et al. Mutations in the activin receptior-like kinase 1 gene in hereditary haemorrhagic telangiectasia type 2. Nature Genet 1996; 13: 189-95.
32. Cole SG, Begbie ME, Wallace GM, Shovlin CL. A new locus for hereditary haemorrhagic telangiectasia (HHT3) maps to chromosome 5. J Med Genet 2005; 42: 577-82.
33. Yamashita H, ten Dijke P, Franzen P, Miyazono K, Heldin CH. Formation of hetero-oligomeric complexes of type I and type II receptors for transforming growth factor beta. J Biol Chem 1994; 269: 20172-8.
34. Derynck R, Zhang YF. Smad-dependent and Smad-independent pathways in TGF-beta family signalling. Nature 2003; 425: 577-84.
35. Goumans MJ, Valdimarsdottir G, Itoh S, Rosendahl A, Sideras P, ten Dijke P. Balancing the activation state of the endothelium via two distinct TGF-beta type I receptors. EMBO J 2002; 21: 1743-53.
36. Goumans MJ, Lebrin F, Valdimarsdottir G. Controlling the angiogenic switch: A balance between two distinct TGF-β receptor signaling pathways. Trends Cardiovasc Med 2003; 13: 301-7.
37. ten Dijke P, Hill CS. New insights into TGF-β-Smad signaling. Trens Biochem Sci 2004; 29: 265-73.
38. Nakao A, Imamura T, Souchelmytskyi S, Kawabata M, Ishisaki A, Oeda E, et al. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J 1997; 16: 5353-62.
39. Suzuki C, Murakami G, Fukuchi M, Shimanuki T, Shikauchi Y, Imamura T, et al. Smurfl regulates the inhibitory activity of Smad7 by targeting Smad7 to the plasma membrane. J Biol Chem 2002; 277: 39919-25.
40. Shi W, Sun C, He B, Xiong W, Shi X, Yao D, et al. GADD34-PPIc recruited by Smad7 dephosphorylates TGF-beta type I receptor. J Cell Biol 2004; 164: 291-300.
41. Lebrin F, Goumans MJ, Jonker L, Carvalho RL, Valdimarsdottir G, Thorikay M, et al. Endoglin promotes endothelial cell proliferation and TGF-beta/ALK1 signal transduction. EMBO J 2004; 23: 4018-28.
42. Pece-Barbara N, Vera S, Kathirkamathamby K, Liebner S, Di Guglielmo GM, Dejana E, et al. Endoglin null endothelial cells proliferate faster and are more responsive to transforming growth factor beta1 with higher affinity receptors and a activated Alk1 pathway. J Biol Chem 2005; 280: 27800-8.
43. Guo B, Slevin M, Li C, Parameshwar S, Liu D, Kumar P, et al. CD105 inhibits transforming growth factor-beta-Smad3 signalling. Anticancer Res 2004; 24: 1337-45.
44. Goumans MJ, Valdimarsdottir G, Itoh S, Lebrin F, Larsson J, Mummery C, et al. Activin receptor-like kinase (ALK)1 is an antagonistic mediator of lateral TGFbeta/ALK5 signaling. Mol Cell 2003; 12: 817-28.
45. Strutz F, Müller GA, Neilson EG. Transdifferentiation: A new angle on renal fibrosis. Exp Nephrol 1996; 4: 267-70.
46. Reeves HL, Friedman SL. Activation of hepatic stellate cells -a key issue in liver fibrosis. Front Biosci 2002; 7: 808-26.
47. Border WA, Ruoslahti E. Transforming growth factor-beta in disease: The dark side of tissue repair. J Clin Invest 1992; 90: 1-7.
48. Roberts AB, Sporn MB. Physiological actions and clinical applications of transforming growth factor-beta (TGF-beta). Growth Factors 1993; 8: 1-9.
49. Ketteler M, Noble NA, Border WA. Transforming growth factor-beta and angiotensin II: The missing link from glomerular hyperfiltration to glomerulosclerosis? Annu Rev Physiol 1995; 57: 279-95.
50. Gressner AM, Weiskirchen R, Breitkopf K, Dooley S. Roles of TGF-β in hepatic fibrosis. Front Biosci 2002; 7: 793-807.
51. Rodríguez-Barbero A, Obreo J, Eleno N, Rodríguez-Peña A, Düwel A, Jerkic M, et al. Endoglin expression in human and rat mesangial cells and its upregulation by TGF-β1. Biochem Biophys Res Com 2001; 23: 142-7.
52. Díez-Marqués L, Ortega-Velázquez R, Langa C, Rodríguez-Barbero A, López-Novoa JM, Lamas S, et al. Expression of endoglin in human mesangial cells: Modulation of extracellular matrix synthesis. Biochem Biophys Acta 2002; 158: 36-44.
53. Obreo J, Díez-Marqués L, Lamas S, Duwell A, Eleno N, Bernabéu C, et al. Endoglin expression regulates basal and TGF-beta1-induced extracellular matrix synthesis in cultures L6E9 myoblasts. Cell Physiol Biochem 2004; 14: 301-10.
54. Rodríguez-Barbero A, Obreo J, Álvarez-Muñoz P, Pandiella A, Bernabéu C, López-Novoa JM. Endoglin modulation of TGF-β1-induced collagen synthesis is dependent on ERK1/2 MAPK activation. Cell Physiol Biochem 2006; 18: 135-42.
55. Gressner AM, Weiskirchen R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-β as major players and therapeutic targets. J Cell Mol Med 2006; 10: 76-99.
56. Cassiman D, Roskams T. Beauty is in the eye of the beholder: Emerging concepts and pitfalls in hepatic stellate cells research. J Hepatol 2002; 37: 527-35.
57. Gressner AM. Perisinusoidal lipocytes and fibrogenesis. Gut 1994; 35: 1331-3.
58. Bataller R, Brenner DA. Liver fibrosis. J Clin Invest 2005; 115: 209-18.
59. Bachem MG, Meyer DH, Schafer W, Riess U, Melchior R, Sell KM, et al. The response of rat liver perisinusoidal lipocytes to polypeptide growth regulator changes with their transdifferentiation into myofibroblasts-like cells in culture. J Hepatol 1993; 18: 40-52.
60. Dooley S, Delvoux B, Lahme B, Mangasser-Stephan K, Gressner AM. Modulation of transforming growth factor β ρesponse and signaling during transdifferentiation of rat hepatic stellate cells to myofibroblasts. Hepatology 2000; 31: 1094-106.
61. Meurer SK, Tihaa L, Lahme B, Gressner AM, Weiskirchen R. Identification of endoglin in rat hepatic stellate cells: New insights into transforming growth factor β receptor signaling. J Biol Chem 2005; 280: 3078-87.
62. Dooley S, Delvoux B, Streckert M, Bonzel L, Stopa M, ten Dijke P, et al. Transforming growth factor β signal transduction in hepatic stellate cells via Smad2/3 phosphorylation, a pathway that is abrogated during in vitro progression to myofibroblasts. FEBS letters 2001; 502: 4-10.
63. Wiercinska E, Wickert L, Denecke B, Said HM, Hamzavi J, Gressner AM, et al. Id1 is a critical mediator in TGF-β-induced transdifferentiation of rat hepatic stellate cells. Hepatology 2006; 43: 1032-41.
64. Clemente M, Núñez O, Lorente R, Rincón D, Matilla A, Salcedo M, et al. Increased intrahepatic and circulating levels of endoglin, a TGF-β1 co-receptor, in patients with chronic hepatitis C virus infection: Relationship to histological and serum markers of hepatic fibrosis. J Viral Hepat 2006; 13: 625-32.
65. Scherner O, Meurer SK, Tihaa L, Gressner AM, Weiskirchen R. Endoglin differentially modulates antagonistic transforming growth factor-beta1 and BMP-7 signaling. J Biol Chem 2007; 282: 13934-43.